Tandem Diabetes Care (TNDM) FY2019 results: revenue $362 million, up 97.0% on the year
Tandem Diabetes Care Inc. (TNDM) reported revenue of $362 million for fiscal 2019, the year ended 31 December 2019, up 97.0% on the year before. Net income was -$25 million, and diluted earnings per share $-0.42. The figures are the company's own, from the 10-K it filed with the SEC on 24 February 2020.
Revenue
$362 million
+97.0% on the year
FY2012FY2019
Operating margin
-4.6%
-24.3% a year earlier
FY2012FY2019
Net income
-$25 million
FY2012FY2019
Diluted EPS
-$0.42
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
362
184
108
+97.0%
Cost of revenue
168
94.0
63.5
+78.7%
Gross profit
194
89.8
44.1
+116.2%
Gross margin
53.6%
48.9%
41.0%
Research and development
45.2
29.2
20.7
+54.6%
Selling, general and administrative
166
105
86.4
+57.5%
Operating income
-16.7
-44.6
-62.9
Operating margin
-4.6%
-24.3%
-58.5%
Pre-tax income
-24.6
-123
-73.0
Income tax
0.1
0.1
0.0
+192.2%
Net income
-24.8
-123
-73.0
Net margin
-6.8%
-66.7%
-67.9%
Diluted EPS
-$0.42
-$2.55
-$12.87
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
41.9
-8.3
-66.1
Capital expenditure
19.5
3.0
5.7
+554.4%
Free cash flow
22.4
-11.3
-71.9
Free cash flow margin
6.2%
-6.1%
-66.8%
Cash from investing
-57.0
-90.7
2.8
Cash from financing
24.2
117
40.4
-79.3%
Depreciation and amortisation
6.1
5.8
6.9
+4.3%
Share-based compensation
58.1
23.7
12.6
+144.7%
Diluted shares, weighted
59m
n/a
n/a
Shares outstanding at period end
59m
58m
10m
+3.2%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
195
131
-29.1
+48.5%
Debt
0.0
0.0
82.7
Operating lease liabilities
14.1
n/a
n/a
Other liabilities
117
75.0
41.8
+56.1%
Total liabilities and equity
326
206
95.3
+58.1%
Fixed assets
32.9
17.2
19.6
+92.0%
Investments
125
87.2
0.5
+43.7%
Cash and equivalents
51.2
41.8
13.7
+22.4%
Receivables
46.6
35.2
20.8
+32.4%
Inventory
49.1
19.9
27.0
+146.6%
Other assets
21.1
5.0
13.8
+319.2%
Total assets
326
206
95.3
+58.1%
10-K for the year ended 31 December 2019, filed 24 February 2020: the filing.